FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012537592> ?p ?o ?g. }

• W3012537592 abstract "Abstract Eptinezumab is a humanized mAb that targets calcitonin gene‐related peptide and is under regulatory review for the prevention of episodic and chronic migraine (EM, CM). It is important to determine whether exposures achieved with intravenous (IV) administration of eptinezumab achieve desired pharmacologic effects. Population pharmacokinetics, including dose‐ and exposure‐response analyses, were performed using patient‐level data from the eptinezumab clinical trial program with IV doses ranging from 10 to 1000 mg in pharmacokinetic analyses or 10 to 300 mg in phase 2/3 clinical studies in patients with EM or CM. Exposure‐response analysis explored the relationship between eptinezumab exposure metrics and efficacy parameters including monthly migraine days. The pharmacokinetic profile of eptinezumab was characterized by rapid attainment of maximum plasma concentration (ie, end of IV administration) and a terminal half‐life of 27 days. Covariate analysis found that patient characteristics had no clinically significant effects on pharmacokinetic parameters and were insufficient to influence dosing. Dose‐ and exposure‐response analyses found exposure with single doses ≥100 mg was associated with greater efficacy compared with doses ≤30 mg and a plateau of effect between 100 and 300 mg. A saturable inhibitory E max model found the exposure over 12 weeks produced by single‐dose eptinezumab 100 and 300 mg exceeded the exposure estimates required to achieve 90% of the maximal efficacy (EC 90 ). This pharmacokinetic analysis of eptinezumab supports dosing every 12 weeks with no adjustment for patient characteristics, including exposures associated with 100‐ or 300‐mg doses producing optimal efficacy effects. The similar efficacy profiles support 100 mg as the lowest effective dose of eptinezumab." @default.
• W3012537592 created "2020-03-23" @default.
• W3012537592 creator A5037987534 @default.
• W3012537592 creator A5039406215 @default.
• W3012537592 creator A5045428639 @default.
• W3012537592 creator A5053828517 @default.
• W3012537592 creator A5060329122 @default.
• W3012537592 creator A5078913596 @default.
• W3012537592 creator A5080570079 @default.
• W3012537592 creator A5081580924 @default.
• W3012537592 date "2020-03-10" @default.
• W3012537592 modified "2023-10-18" @default.
• W3012537592 title "Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine" @default.
• W3012537592 cites W2001650386 @default.
• W3012537592 cites W2013190669 @default.
• W3012537592 cites W2111354448 @default.
• W3012537592 cites W2148445312 @default.
• W3012537592 cites W2169170125 @default.
• W3012537592 cites W2473505427 @default.
• W3012537592 cites W2550207834 @default.
• W3012537592 cites W2594986299 @default.
• W3012537592 cites W2623864543 @default.
• W3012537592 cites W2718582600 @default.
• W3012537592 cites W2728093281 @default.
• W3012537592 cites W2736411845 @default.
• W3012537592 cites W2737197277 @default.
• W3012537592 cites W2757941745 @default.
• W3012537592 cites W2766819558 @default.
• W3012537592 cites W2770965214 @default.
• W3012537592 cites W2792811290 @default.
• W3012537592 cites W2795835597 @default.
• W3012537592 cites W2800794691 @default.
• W3012537592 cites W2803715733 @default.
• W3012537592 cites W2805181790 @default.
• W3012537592 cites W2895868360 @default.
• W3012537592 cites W2898072840 @default.
• W3012537592 cites W2901687990 @default.
• W3012537592 cites W2931739625 @default.
• W3012537592 cites W2955283194 @default.
• W3012537592 cites W3007053288 @default.
• W3012537592 doi "https://doi.org/10.1002/prp2.567" @default.
• W3012537592 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7064329" @default.
• W3012537592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32155317" @default.
• W3012537592 hasPublicationYear "2020" @default.
• W3012537592 type Work @default.
• W3012537592 sameAs 3012537592 @default.
• W3012537592 citedByCount "33" @default.
• W3012537592 countsByYear W30125375922020 @default.
• W3012537592 countsByYear W30125375922021 @default.
• W3012537592 countsByYear W30125375922022 @default.
• W3012537592 countsByYear W30125375922023 @default.
• W3012537592 crossrefType "journal-article" @default.
• W3012537592 hasAuthorship W3012537592A5037987534 @default.
• W3012537592 hasAuthorship W3012537592A5039406215 @default.
• W3012537592 hasAuthorship W3012537592A5045428639 @default.
• W3012537592 hasAuthorship W3012537592A5053828517 @default.
• W3012537592 hasAuthorship W3012537592A5060329122 @default.
• W3012537592 hasAuthorship W3012537592A5078913596 @default.
• W3012537592 hasAuthorship W3012537592A5080570079 @default.
• W3012537592 hasAuthorship W3012537592A5081580924 @default.
• W3012537592 hasBestOaLocation W30125375921 @default.
• W3012537592 hasConcept C112705442 @default.
• W3012537592 hasConcept C118303440 @default.
• W3012537592 hasConcept C126322002 @default.
• W3012537592 hasConcept C163170386 @default.
• W3012537592 hasConcept C170493617 @default.
• W3012537592 hasConcept C2777288759 @default.
• W3012537592 hasConcept C2778541695 @default.
• W3012537592 hasConcept C2908647359 @default.
• W3012537592 hasConcept C535046627 @default.
• W3012537592 hasConcept C71924100 @default.
• W3012537592 hasConcept C98274493 @default.
• W3012537592 hasConcept C99454951 @default.
• W3012537592 hasConceptScore W3012537592C112705442 @default.
• W3012537592 hasConceptScore W3012537592C118303440 @default.
• W3012537592 hasConceptScore W3012537592C126322002 @default.
• W3012537592 hasConceptScore W3012537592C163170386 @default.
• W3012537592 hasConceptScore W3012537592C170493617 @default.
• W3012537592 hasConceptScore W3012537592C2777288759 @default.
• W3012537592 hasConceptScore W3012537592C2778541695 @default.
• W3012537592 hasConceptScore W3012537592C2908647359 @default.
• W3012537592 hasConceptScore W3012537592C535046627 @default.
• W3012537592 hasConceptScore W3012537592C71924100 @default.
• W3012537592 hasConceptScore W3012537592C98274493 @default.
• W3012537592 hasConceptScore W3012537592C99454951 @default.
• W3012537592 hasIssue "2" @default.
• W3012537592 hasLocation W30125375921 @default.
• W3012537592 hasLocation W30125375922 @default.
• W3012537592 hasLocation W30125375923 @default.
• W3012537592 hasLocation W30125375924 @default.
• W3012537592 hasOpenAccess W3012537592 @default.
• W3012537592 hasPrimaryLocation W30125375921 @default.
• W3012537592 hasRelatedWork W1499958231 @default.
• W3012537592 hasRelatedWork W188950588 @default.
• W3012537592 hasRelatedWork W1987721600 @default.
• W3012537592 hasRelatedWork W2004325424 @default.
• W3012537592 hasRelatedWork W2591456584 @default.
• W3012537592 hasRelatedWork W2793520024 @default.
• W3012537592 hasRelatedWork W2969843942 @default.
• W3012537592 hasRelatedWork W3021369409 @default.

• next